Deventer 2006.

Methods	A randomised, placebo‐controlled, double‐blind, two‐dose ranging multi‐center study (N = 112)
Participants	Adult patients > 18 years with active distal UC and a left‐sided disease flare (mucosal involvement 5‐50 cm for the anal verge) Disease activity index (DAI) score score between 4‐10 that included an abnormal endoscopic score, and were receiving, alone or in combination, stable doses of oral mesalazine (> 30 days), AZA (> 60 days), or 6‐MP (> 60 days) prior to the study
Interventions	Group 1: 120 mg alicaforsen daily for 10 days and then every other day thereafter (n = 22) Group 2: 240 mg alicaforsen every other day (n = 23) Group 3: 240 mg alicaforsen daily for 10 days and then every other day (n = 23) Group 4: 240 mg alicaforsen daily (n = 22) Group 5: placebo (n = 22)
Outcomes	Primary outcome: UCDAI at week 6 Secondary outcomes: clinical improvement, relapse rates and durability of response
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not described
Allocation concealment (selection bias)	Unclear risk	Not described
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Not described beyond 'double‐blind'
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Not described
Incomplete outcome data (attrition bias) All outcomes	Low risk	Drop‐outs balanced across intervention groups with similar reasons for withdrawal
Selective reporting (reporting bias)	Low risk	All expected outcomes were reported
Other bias	Low risk	The study appears to be free of other sources of bias